Bristol Myers Squibb Shares Fall 2% After Patient Death in MS Trial
Bristol Myers Squibb disclosed a patient death in its early-stage Breakfree-2 study of experimental CAR T therapy zolacabtagene autoleucel for multiple sclerosis. Its shares fell 2% on Friday.
Bristol Myers Squibb (BMY) shares fell 2% on Friday after the company reported a patient death in the early-stage Breakfree-2 study of its experimental CAR T-cell therapy, zolacabtagene autoleucel, for multiple sclerosis. The patient, who had highly active relapsing MS, died after…